ASH News Daily 2012 - Saturday, December 8, 2012 - (Page A-1)
ASH NEWS DAILY
54th Annual Meeting of the American Society of Hematology
®
Read this issue online at
www.hematology.org/ashnewsdaily2012_saturday
SCHEDULE
11:15 – 12:15 p.m.
Grassroots Network Lunch
International Ballroom D, North Tower
Omni Hotel at CNN Center
12:30 – 1:30 p.m.
Ham-Wasserman Lecture
Hall B5, Level 1, Building B, GWCC
2:00 – 3:30 p.m.
Special Symposium: Quality Improvement
A103, Level 1, Building A
GWCC
4:00 – 5:30 p.m.
Special Symposium on Epigenetics in
Hematopoiesis
A103, Level 1, Building A
5:30 – 7:30 p.m.
Welcome Reception
Poster Hall
Hall B1-B2, Level 1, Building B
GWCC
6:00 – 7:30 p.m.
Practice Forum
International Ballroom D, North Tower
Omni Hotel at CNN Center
6:30 – 9:00 p.m.
Promoting Minorities in Hematology
Presentations and Reception
Grand Ballroom A-D, M4/Grand Ballroom
Level, North Tower
Omni Hotel at CNN Center
7:30 – 8:30 p.m.
Practice Forum Reception
Grand Ballroom A-B, M2/Grand Ballroom
Level, North Tower
Omni Hotel at CNN Center
ASH shuttle buses remind attendees to “Fight for Hematology” as they
drive in front of the Georgia World Congress Center on Friday morning.
ASH – The OTHER Helpful Hardware Place
BY ANDREW D. LEAVITT, MD
Y
underlying
ou know the presenting signs
and symptoms for myriad
hematologic disorders, their
pathophysiology, and
the latest medications and practice
guidelines. You are revered as the
go-to hematologist in your area
when all others are stumped. But do
you have the right environmental
structure, the right toolkit, to translate
that wealth of knowledge and
expertise into objective, high-quality
patient care in your practice? If
you are like many of us, the answer
is no.
With the current and upcoming
changes in health-care delivery and
reimbursement, this toolkit will be
essential for you to continue doing
what you enjoy, and to do it well.
To that end, today, at 2:00 p.m. in
Room A103, on Level 1 of Building
A in the Georgia World Congress
Center, you can update your wealth
of knowledge at the “Special Symposium
on Quality Improvement –
A Toolkit for Hematology Practice.”
Symposium Co-chairs John Strouse,
MD, PhD, of Johns Hopkins University,
Baltimore, MD, and Wendy
Lim, MD, of McMaster University,
Hamilton, ON, are members of the
ASH Subcommittee on Quality of
Care and have assembled an outstanding
team to provide you with
practical quality improvement tools.
Charles J. Homer, MD, from the
National Initiative for Children’s
Healthcare Quality, Boston, MA, will
kick off the symposium with an insightful
and practical overview of
the principles and implementation
tools necessary to achieve real quality
health-care outcome improvement.
Dr. Homer’s presentation,
»» QUALITY Page A-5
The Ham-Wasserman Lecture Reveals
the UK Point of View on AML
BY JENNA D. GOLDBERG, MD
IN THIS SECTION
Exemplary Service
Award
A-3
Pediatric Leukemias
A-4
Myeloma
A-8
TTP/HUS
A-14
Transplantation
A-18
for many years. Patients who are
deemed fit enough generally receive
induction therapy affectionately
termed “7+3” with cytarabine
combined with an anthracycline.
Consolidation therapy is usually
additional cytarabine or an allogeneic
stem cell transplant for otherwise
healthy patients with high-risk
disease. This outdated paradigm
will be challenged by Dr. Alan K.
Burnett in today’s Ham-Wasserman
Lecture.
T
In this afternoon’s lecture, Dr.
Burnett will discuss the personalization
of leukemia therapy. He will
review recent data that may suggest
that there are better induction op-
he standard therapy for acute
myeloid leukemia (AML)
has
remained unchanged
tions than the traditional “7+3” approach,
particularly for younger patients.
A few of the options that he
will review include daunorubicin
intensification, inclusion of novel
nucleoside analogues (fludarabine/
clofarabine/cladribine), and the incorporation
of antibody-directed
chemotherapy using gemtuzumab
ozogamicin, which the Medical Research
Council (MRC) has adopted
as a standard of care, in spite of the
regulatory limitations. The strategy
for determining who receives an allogeneic
transplant in first remission
will be addressed, including incorporating
molecular studies and minimal
residual disease testing. Dr. Burnett
will also discuss the implications of
molecular testing on treatment, including
targeting FLT3/mTOR and
BCL2 with all-trans-retinoic acid as
examples, although none has yet
Ham-Wasserman Lecture
12:30 p.m.
Hall B5, Building B, Level 1
Georgia World
Congress Center
shown clear benefit in a randomized
trial. Finally, he will talk about
the lack of progress in improving
outcomes in older patients and the
novel “pick-a-winner” design he
helped develop that has the potential
to more rapidly evaluate new
treatments or combinations for this
patient group, which may apply to
»» HAM-WASSERMAN Page A-5
http://www.hematology.org/ashnewsdaily2012_saturday
Table of Contents for the Digital Edition of ASH News Daily 2012 - Saturday, December 8, 2012
ASH News Daily 2012 - Saturday, December 8, 2012
https://www.nxtbookmedia.com